{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T07:59:03Z","timestamp":1791273543541,"version":"4.1.0"},"reference-count":57,"publisher":"Wiley","issue":"1","license":[{"start":{"date-parts":[[2012,5,10]],"date-time":"2012-05-10T00:00:00Z","timestamp":1336608000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Mycoses"],"published-print":{"date-parts":[[2013,1]]},"abstract":"<jats:title>Summary<\/jats:title><jats:p>Recent guideline recommendations on the management of candidaemia provide valuable treatment guidance for routine clinical practice, but need to be interpreted in the light of the actual situation of the patient and the local epidemiology of fungal infections. Echinocandins emerge as the generally preferred primary treatment. Treatment should be initiated immediately after notification of a <jats:italic>Candida<\/jats:italic>\u2010positive blood culture in all patients. Ambiguous issues include the definition of optimum duration of treatment, the indication and time point to step down to oral azoles, catheter management, and the appropriate approach in critically ill patients at high risk for candidaemia in the absence of definitive proof of infection. Patients with clinical suspicion of antifungal treatment failure need prompt workup for adequacy of treatment, focal sources of sustained infection and potential superinfection.<\/jats:p>","DOI":"10.1111\/j.1439-0507.2012.02208.x","type":"journal-article","created":{"date-parts":[[2012,5,11]],"date-time":"2012-05-11T03:24:38Z","timestamp":1336706678000},"page":"11-20","source":"Crossref","is-referenced-by-count":16,"title":["Practical considerations on current guidelines for the management of non\u2010neutropenic adult patients with candidaemia"],"prefix":"10.1111","volume":"56","author":[{"given":"A.","family":"Gl\u00f6ckner","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"O. A.","family":"Cornely","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2012,5,10]]},"reference":[{"key":"e_1_2_12_2_2","doi-asserted-by":"publisher","DOI":"10.1086\/421946"},{"key":"e_1_2_12_3_2","doi-asserted-by":"publisher","DOI":"10.1001\/archinte.1988.00380120094019"},{"key":"e_1_2_12_4_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-9343(02)01248-2"},{"key":"e_1_2_12_5_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF02113499"},{"key":"e_1_2_12_6_2","doi-asserted-by":"publisher","DOI":"10.1086\/496922"},{"key":"e_1_2_12_7_2","doi-asserted-by":"publisher","DOI":"10.1086\/378745"},{"key":"e_1_2_12_8_2","first-page":"65","article-title":"Septic shock due to candidemia: outcomes and predictors of shock development","volume":"3","author":"Guzman JA","year":"2011","journal-title":"J Clin Med Res"},{"key":"e_1_2_12_9_2","doi-asserted-by":"publisher","DOI":"10.1007\/s11908-011-0204-x"},{"key":"e_1_2_12_10_2","doi-asserted-by":"publisher","DOI":"10.1086\/596757"},{"key":"e_1_2_12_11_2","unstructured":"HerbrechtR Fl\u00fcckingerU GachotB RibaudP ThiebautA CordonnierC.Antifungal therapy in leukemia patients guidelines update ECIL\u20104.http:\/\/www.ebmt.org\/Contents\/Resources\/Library\/ECIL\/Documents\/ECIL%204Update%202011%20Antifungal%20therapy.pdf[accessed on 2 May 2012]."},{"key":"e_1_2_12_12_2","unstructured":"UllmannAJ Cuenca\u2010EstrellaM LortholaryO CornelyOA RoilidesE.Presentation of the ESCMID diagnostic and management guidelines for Candida diseases 2011. Educational workshop EW 16; ECCMID 2011."},{"key":"e_1_2_12_13_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1439-0507.2011.02040.x"},{"key":"e_1_2_12_14_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.49.9.3640-3645.2005"},{"key":"e_1_2_12_15_2","doi-asserted-by":"publisher","DOI":"10.1086\/504810"},{"key":"e_1_2_12_16_2","unstructured":"KumarA SkrobikI GuzmanJet\u00a0al.The high mortality of Candida septic shock is explained by excessive delays in initiation of antifungal therapy. ICAAC 2007; abstract K\u20102174."},{"key":"e_1_2_12_17_2","doi-asserted-by":"publisher","DOI":"10.1097\/MJT.0b013e3181a1afb7"},{"key":"e_1_2_12_18_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00945-09"},{"key":"e_1_2_12_19_2","doi-asserted-by":"publisher","DOI":"10.1097\/00003246-199906000-00019"},{"key":"e_1_2_12_20_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa066906"},{"key":"e_1_2_12_21_2","doi-asserted-by":"crossref","unstructured":"KettDH ShorrAF ReboliAC ReismanAL BiswasP SchlammHT.Anidulafungin compared with fluconazole therapy incritically ill patients. ISICEM2010; Poster A75.","DOI":"10.1186\/cc8304"},{"key":"e_1_2_12_22_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01031-09"},{"key":"e_1_2_12_23_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01128-10"},{"key":"e_1_2_12_24_2","unstructured":"Gl\u00f6cknerA AbelP BernhardtH ZimmermannK WiersbitzlyM.Mycological findings upon Admission to A non\u2010surgical ICU. ICAAC2002; Poster M\u2010874."},{"key":"e_1_2_12_25_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkq136"},{"key":"e_1_2_12_26_2","unstructured":"PaivaJA RuhnkeM MeerssemanW.Anidulafungin for treatment of candidemia\/invasive candidiasis in selected intensive care unit populations. SCCM Annual Meeting 2010; Abstract 297."},{"key":"e_1_2_12_27_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.diagmicrobio.2010.06.015"},{"key":"e_1_2_12_28_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2011.02.016"},{"key":"e_1_2_12_29_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1439-0507.2011.02044.x"},{"key":"e_1_2_12_30_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjmed.2011.11.001"},{"key":"e_1_2_12_31_2","unstructured":"ArendrupMC.Susceptibility breakpoints and resistance to antifungals among Candida species \u2010 where are we in 2011?ECCMID2011; presentation S428."},{"key":"e_1_2_12_32_2","unstructured":"European Commitee on Antimicrobial Susceptibility Testing.Antimicrobials for Candida infections \u2013 EUCAST clinical MIC breakpoints v.3.0 2011\u201004\u201027.http:\/\/www.srga.org\/eucastwt\/MICTAB\/EUCASTclinical MIC breakpoints \u2010 antimicrobials for Candida infections.htm [accessed on 2 May 2012]."},{"key":"e_1_2_12_33_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.drup.2011.01.004"},{"key":"e_1_2_12_34_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.mimet.2011.05.019"},{"key":"e_1_2_12_35_2","doi-asserted-by":"publisher","DOI":"10.1053\/jhin.2001.1151"},{"key":"e_1_2_12_36_2","doi-asserted-by":"publisher","DOI":"10.1128\/CMR.17.2.255-267.2004"},{"key":"e_1_2_12_37_2","unstructured":"AndesDR SafdarN BaddleyJet\u00a0al.Impact Of Therapy On Mortality Across Candida spp In Patients With Invasive Candidiasis From Randomized Clinical Trials: A Patient Level Analysis. Presentation M\u20101312; 50th ICAAC Boston MA USA September 11\u201015 2010."},{"key":"e_1_2_12_38_2","doi-asserted-by":"publisher","DOI":"10.1097\/CCM.0b013e31818b3477"},{"key":"e_1_2_12_39_2","doi-asserted-by":"publisher","DOI":"10.1080\/00365540510026814"},{"key":"e_1_2_12_40_2","doi-asserted-by":"publisher","DOI":"10.1093\/clinids\/20.3.571"},{"key":"e_1_2_12_41_2","doi-asserted-by":"publisher","DOI":"10.1093\/clinids\/21.4.994"},{"key":"e_1_2_12_42_2","doi-asserted-by":"publisher","DOI":"10.1086\/514609"},{"key":"e_1_2_12_43_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1469-0691.2007.01758.x"},{"key":"e_1_2_12_44_2","doi-asserted-by":"publisher","DOI":"10.1007\/s10096-008-0546-y"},{"key":"e_1_2_12_45_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhin.2005.02.009"},{"key":"e_1_2_12_46_2","doi-asserted-by":"publisher","DOI":"10.1086\/653935"},{"key":"e_1_2_12_47_2","doi-asserted-by":"publisher","DOI":"10.1002\/yea.1860"},{"key":"e_1_2_12_48_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01569-10"},{"key":"e_1_2_12_49_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00697-10"},{"key":"e_1_2_12_50_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1567-1364.2010.00618.x"},{"key":"e_1_2_12_51_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa021585"},{"key":"e_1_2_12_52_2","doi-asserted-by":"publisher","DOI":"10.1086\/520980"},{"key":"e_1_2_12_53_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(05)67490-9"},{"key":"e_1_2_12_54_2","unstructured":"DavisS KouzaA WiegandT VazquezJConversion of intravenous echinocandins to oral azoles for invasive candidiasis: impact on outcomes and resource utilisation. ECCMID2008; Abstract O458."},{"key":"e_1_2_12_55_2","unstructured":"Analysis of data from the randomized trial of anidulafungin vs. fluconazole for invasive candidiasis (Reboliet\u00a0al.[19]; Pfizer data on file)."},{"key":"e_1_2_12_56_2","unstructured":"Micafungin (Mycamine\u00ae) summary of product characteristics; August 2011."},{"key":"e_1_2_12_57_2","unstructured":"Anidulafungin (Ecalta\u00ae) summary of product characteristics; July 2011."},{"key":"e_1_2_12_58_2","unstructured":"Caspofungin (Cancidas\u00ae) summary of product characteristics; November 2010."}],"container-title":["Mycoses"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1439-0507.2012.02208.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1439-0507.2012.02208.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,30]],"date-time":"2023-10-30T03:33:35Z","timestamp":1698636815000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1439-0507.2012.02208.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,5,10]]},"references-count":57,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2013,1]]}},"alternative-id":["10.1111\/j.1439-0507.2012.02208.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1439-0507.2012.02208.x","archive":["Portico"],"relation":{},"ISSN":["0933-7407","1439-0507"],"issn-type":[{"value":"0933-7407","type":"print"},{"value":"1439-0507","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,5,10]]}}}